Geographic Atrophy

New analysis reveals the ellipsoidal zone's role in predicting geographic atrophy progression, enabling timely interventions to protect photoreceptors.

New research links diffuse-trickling patterns in fundus autofluorescence to increased ellipsoidal zone loss, highlighting potential biomarkers for rapid geographic atrophy progression.

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in geographic atrophy patients, highlighting early intervention opportunities.

A recent study reveals how geographic atrophy affects patients' vision and quality of life, highlighting their coping strategies and need for better resources.

Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.

In this Q&A, Luke Lindsell, OD, MD, shares his insights on emerging therapies in retina, the evolving role of optometrists in retinal disease management, and the importance of comanagement in patient care.

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ophthalmology and patient care.

Eyecyte-RPE is a suspension of human induced pluripotent stem cell–derived retinal pigment epithelial cells.

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency

The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114.

Investigators advised clinicians of the potential for dystrophies that mimic age-related macular degeneration and other atrophic macular pathologies to be incorrectly diagnosed, which can impact treatment.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that was followed by a TAE.

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, a first-in-class mitochondria-targeted investigational therapeutic.

Survey examines experiences and perceptions of patients living with GA.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

Among these eyes, 18.9% of eyes developed nAMD within 36 months.

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.

The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.

ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in patients with GA

The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.